phosphonoacetic acid has been researched along with Cholera Infantum in 6 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Excerpt | Relevance | Reference |
---|---|---|
"Foscarnet was administered as a continuous infusion of 200 mg/kg (prior to 1988) or as an intermittent infusion of 60 mg/kg t." | 2.67 | Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet. ( Blanshard, C, 1992) |
"Four of ten patients with colorectal cancer responded to the treatment (four partial responses), of whom three had been treated previously." | 2.67 | A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. ( Ardalan, B; Benedetto, P; Feun, L; Fodor, M; Livingstone, A; Morrell, L; Richman, S; Savaraj, N; Sridhar, KS; Waldman, S, 1991) |
"5-Fluorouracil (FUra) is a clinically useful antineoplastic agent." | 1.27 | Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid. ( Casper, ES; Martin, DS; Vale, K; Williams, LJ; Young, CW, 1983) |
" Since toxicity is a prominent impediment, the possibility of therapeutic synergy may perhaps be explored at drastically reduced doses of PALA, combined with other modulating measures." | 1.27 | Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer. ( Camacho, FJ; Engstrom, PF; Green, MD; Greenwald, ES; Kaplan, BH; Muggia, FM; Wernz, JC, 1987) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (66.67) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Casper, ES | 2 |
Vale, K | 1 |
Williams, LJ | 1 |
Martin, DS | 1 |
Young, CW | 2 |
Gralla, RJ | 1 |
Natale, RB | 1 |
Yagoda, A | 1 |
Blanshard, C | 1 |
Ardalan, B | 1 |
Sridhar, KS | 1 |
Benedetto, P | 1 |
Richman, S | 1 |
Waldman, S | 1 |
Morrell, L | 1 |
Feun, L | 1 |
Savaraj, N | 1 |
Fodor, M | 1 |
Livingstone, A | 1 |
Muggia, FM | 1 |
Camacho, FJ | 1 |
Kaplan, BH | 1 |
Green, MD | 1 |
Greenwald, ES | 1 |
Wernz, JC | 1 |
Engstrom, PF | 1 |
Markman, M | 1 |
Chan, TC | 1 |
Cleary, S | 1 |
Howell, SB | 1 |
2 trials available for phosphonoacetic acid and Cholera Infantum
Article | Year |
---|---|
Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Female; Foscarnet; | 1992 |
A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; B | 1991 |
4 other studies available for phosphonoacetic acid and Cholera Infantum
Article | Year |
---|---|
Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Blood Cell Count; Carcinoma; Drug Admin | 1983 |
Phase I trial of PALA.
Topics: Antineoplastic Agents; Aspartic Acid; Brain Diseases; Diarrhea; Dose-Response Relationship, Drug; Ga | 1980 |
Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Central Nervous System D | 1987 |
Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dipyr | 1987 |